Azenta, Inc. · NASDAQ:AZTA

Azenta — Q3 2024 Earnings Presentation

14 slides from Azenta's earnings presentation, Aug 6, 2024

  1. Slide 1: Conference Call Third Quarter Financial Results

    Conference Call Third Quarter Financial Results August 6, 2024 1 © 2024 Azenta, Inc. • All rights reserved

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co

  3. Slide 3: Azenta Life Sciences Q3 2024 Financial Overview

    Azenta Life Sciences Q3 2024 Financial Overview Continuing Operations – Quarter Ended June 30, 2024 Q3’24 Profitability Balance Sheet and Q3’24 Revenue and Cash Flow Capital Allocation • Revenue of $173M, up 4% YoY on a • Non-GAAP EPS of $0.16 • Strong balance sheet with cash balance reported and 5%

  4. Slide 4: Azenta Operating Performance

    Azenta Operating Performance Continuing Operations – Quarter Ended June 30, 2024 Total Azenta OrganicQ1’24 GrowthRevenue Growth (YtY) Non-GAAP Q3'23 Q3'24 YtY Revenue 166 173 4% Q3 '2 3 Q3 '2 4 Y tY Gross profit 76 78 3% % 45.6% 45.2% (0.4) pts. Reported Q1'23 166 Q1'24 173 YtY 4% FX Reported 178 15

  5. Slide 5: Q3 2024 Revenue Summary

    Q3 2024 Revenue Summary Sample Management Solutions (“SMS”) Sample Management Solutions 47% • Organic growth of 13% in Storage and 5% in Products • ~40% organic growth in Cryogenic Stores • $81 Million and 17% in C&I • 7% YoY reported • 7% Organic Multiomics Multiomics • $173 Million • 4% YoY report

  6. Slide 6: Summary Consolidated Balance Sheet

    Summary Consolidated Balance Sheet Balance Sheet Q1’24 Revenue Growth (YtY) Highlights Mar Jun $ millions 2024 2024 QtQ Cash, restricted cash, short term marketable securities 825 599 (226) • $754M cash, cash equivalents, Q1'23 Q1'24 and YtY Accounts receivable, net 155 168 13 marketable securities

  7. Slide 7: Summary Consolidated Cash Flow

    Summary Consolidated Cash Flow Cash Flow Q1’24 Revenue Growth (YtY) Highlights $ millions Q3'24 Cash, restricted cash and marketable securities - Beginning 975 • Operating cash flow of Q1'24 Q1'23 $2M YtY Net income (7) • Negative $5M178 of Free cash flow Reported 154 (13%) Impairment of goodwill an

  8. Slide 8: Fiscal Year 2024 Guidance

    Fiscal Year 2024 Guidance 2024 Guidance May 8, 2024 August 6, 2024 Comments • Revenue lower due to slower timing of order conversion in B Medical and timing of shipments within our OEM line of business Organic: (1%) to 1% Organic: (2%) to (1%) Revenue Revenue: $659M to $671M Revenue: $652M to $658M

  9. Slide 9: Appendix

    Appendix 9 © 2024 Azenta, Inc. • All rights reserved

  10. Slide 10: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions, except EPS Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Revenue 178.4 148.4 165.9 172.4 665.1 154.3 159.1 172.8 GAAP gross profit 73.9 53.2 68.0 68.0 263.1 61.5 63.4 69.1 Gross profit margin 41.4% 35.9%

  11. Slide 11: GAAP to Non-GAAP Reconciliation - Segments

    GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions, except EPS Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Multiomics Revenue 61.1 62.2 63.8 61.1 248.3 62.7 62.2 63.6 Gross profit 27.7 27.0 28.3 26.8 109.8 28.5 27.7 29.2 Gross profit margin 45.4% 43.4% 44.3%

  12. Slide 12: GAAP to Non-GAAP Reconciliation – Continued

    GAAP to Non-GAAP Reconciliation – Continued Continuing Operations – Segments $ millions, except EPS Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY24 Q2 FY24 Q3 FY24 B Medical Revenue 41.8 15.1 26.8 29.4 113.1 12.6 22.8 28.5 GAAP gross profit 14.1 (1.3) 4.8 2.9 20.5 (0.2) 2.7 3.6 Gross profit margin 33.7

  13. Slide 13: Net Income to Adjusted EBITDA Reconciliation

    Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Net income (11.2) (4.9) (1.5) 3.4 (14.3) (15.7) (136.9) (6.6) (Income) Loss from discontinued operations, net of tax - 2.9 (1.0) (0.6) 1.4 - - - Net income (Loss

  14. Slide 14: Calculation of Organic Revenue

    Calculation of Organic Revenue Continuing Operations Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Revenue 28% 2% 25% 25% (13%) 7% 4% Acquisitions/divestitures (33%) (13%) (24%) (22%) (1%) 0% 0% Currency exchange rates 4% 3% 0% (1%) (1%) (0%) 1% Organic revenue (1%) (8%) 2% 2% (15%) 7% 5%

Azenta — Q3 2024 Earnings Presentation on 6ix